newsfilter
← Latest News
GlobeNewswire·

Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results

PRVA
  • Privia Health Group reported 2Q'26 net income of $9.0 million, a 236.7% increase from $2.7 million in 2Q'25.
  • Adjusted EBITDA for 2Q'26 reached $37.4 million, up 29.1% from $29.0 million in 2Q'25.
  • Full-year 2026 guidance was raised for all key financial metrics, including attributed lives, practice collections, GAAP revenue, care margin, platform contribution, and adjusted EBITDA.
  • Total revenue for the three months ended June 30, 2026, was $632.6 million, representing a 21.4% year-over-year increase.
  • Net income for the six months ended June 30, 2026, totaled $12.1 million, an 75.4% increase from $6.9 million in the prior year period.
  • Six-month 2026 total revenue reached $1,236.5 million, up 23.5% from $1,001.3 million in 2025.
  • Implemented providers grew to 5,644 as of June 30, 2026, an 10.1% increase from 5,125 in the prior year.
  • Value-based care attributed lives increased to 1,647,000 in 2Q'26, up 19.2% from 1,382,000 in 2025.
  • Practice collections for the quarter were $970.0 million, a 12.4% increase, while six-month collections reached $1,884.8 million.
  • Care margin for 2Q'26 was $132.1 million, a 14.7% increase, with six-month care margin totaling $260.9 million.
  • Platform contribution for the quarter was $69.0 million, up 20.1%, and $136.0 million for the six-month period.
  • GAAP revenue guidance for 2026 was raised to a high end of $2,450 million, up from the previous high of $2,450 million (previously $2,350 million low).
  • Care margin guidance for 2026 was raised to a mid-to-high end range of $515 million to $530 million.
  • Adjusted EBITDA guidance for 2026 was raised to a mid-to-high end range of $145 million to $155 million.
  • The company expects 70-80% of 2026 adjusted EBITDA to convert to free cash flow, subject to MSSP cash settlement timing.
  • Non-cash stock compensation expense for 2Q'26 was $19.4 million, compared to $18.8 million in 2Q'25.
  • Non-cash stock compensation expense for the six months ended June 30, 2026, was $41.3 million, up from $36.6 million in 2025.
  • Cash and cash equivalents at June 30, 2026, were $412.2 million, a decrease from $479.7 million at year-end 2025.
  • Privia Health hosts a conference call on August 6, 2026, at 8:00 am ET to discuss results and outlook.